Introduction: Depression comorbid with chronic disease may be mediated by inflammation. We sought to characterize relationships between inflammatory biomarkers and depressive symptoms in patients with chronic kidney disease and end-stage kidney disease.Methods: A systematic literature search was conducted by 2 authors up to March 19, 2019, for studies of patients with chronic kidney disease or end-stage kidney disease evaluating circulating inflammatory biomarkers associated with depression of chronic disease: albumin, C-reactive protein (CRP), highsensitivity CRP, interleukin-6 (IL-6), tumor necrosis factor-a, and interleukin-1. Standardized mean differences in biomarkers between individuals with and without depression were computed and analyzed using mixed effects models. Correlations between biomarkers and the severity of depressive symptoms were computed.Results: Thirty-four studies (5652 participants) compared biomarkers between depressed and nondepressed individuals. Individuals with depression had lower albumin levels (standardized mean difference, À0.37; 95% confidence interval [CI], À0.61 to À0.13), higher CRP levels (standardized mean difference, 0.76; 95% CI, 0.16-1.37), and higher IL-6 levels (standardized mean difference, 0.42; 95% CI, 0.21-0.63). Studies were heterogeneous for albumin, CRP, high-sensitivity CRP, and tumor necrosis factora. Twenty-three studies (3047 participants) investigated correlations between biomarkers and depressive symptoms. The severity of depressive symptoms correlated with albumin (Z ¼ À0.25; 95% CI, À0.36 to À0.14), high-sensitivity CRP (Z ¼ 0.28; 95% CI, 0.13-0.43), and IL-6 (Z ¼ 0.34; 95% CI, 0.18-0.49). There was heterogeneity across studies of IL-6. Only 6 studies (321 participants) investigated the effect of antidepressant treatment on inflammatory biomarkers, which was insufficient to combine in meta-analysis.
Conclusion:Lower albumin and higher IL-6 were associated with both the presence and severity of depression, CRP with the presence of depression, and high-sensitivity CRP with the severity of depressive symptoms. The effect of interventions to lower inflammation in patients with kidney disease and depression deserves investigation.